Suzhou Zelgen Biopharmaceuticals Co., Ltd. (688266.SS) SHH

Currency In CNY

AD

Valuation

Market Cap24.42B
Enterprise Value23.54B
P/E Ratio58.85
PEG Ratio0.16
Price/Sales Ratio19.71
Price/Book Ratio18.79
Enterprise/Revenue18.95
Enterprise/EBITDA56.35

Fiscal Year

Fiscal YearDecember 31, 2025
Most Recent QuarterJune 30, 2026

Profitability

Profit Margin0.34
Operating Margin0.32
AD

Management Effectiveness

Return On Assets0.16
Return On Equity0.39

Income Statement

Revenue812.73M
Revenue/Share6.2
Gross Profit732.85M
EBITDA-191.04M
Net Income-162.95M
Diluted EPS-0.62

Balance Sheet

Total Cash2.47B
Total Cash/Share9.33
Total Debt851.71M
Total Debt/Equity0.5
Current Ratio2.5
Book Value Per Share6.53

Price History

52-Week Change11.48
52-Week High160
52-Week Low75.1
Moving Average 50 Days114.59
Moving Average 200 Days101.12

Statistics

Average Volume6.63M
Shares Outstanding264.71M
% Held by InstitutionsN/A

Dividend And Splits

Trailing Annual Dividend Rate0
Trailing Annual Dividend Yield0
Payout Ratio0.02
Last Split FactorN/A
Last Split DateN/A
AD